Xi'an firm aces key assessment for virus nucleic acid tests

The results of the external quality assessment (EQA) for COVID-19 nucleic acid testing, organized by the National Center for Clinical Laboratories of the National Health and Health Commission, were recently formally announced.

Both reagents produced by Xi’an KingMed Diagnostics Group Co passed the assessment with full marks, proving that the company has professional detection technical strength and strict quality control abilities in vitally important COVID-19 nucleic acid testing.

The EQA qualification mainly evaluates a laboratory's ability to test for COVID-19 nucleic acid, focusing on the analytical performance in laboratory tests, including analysis on sensitivity and specificity.

After the COVID-19 outbreak, Xi'an KingMed Diagnostics Group Co was approved to carry out nucleic acid testing for the first time -- and was confirmed by the Xi'an epidemic prevention and control headquarters as one of two screening and testing implementation units in the city.

It was then approved by the Health Commission of Shaanxi Province to be among the first batch of third-party nucleic acid testing agencies in the province.

Officials said it has organized prevention and control screening, re-inspection and testing services and worked with airports on prevention and control screening of inbound passenger flows.

To date, Xi'an KingMed Diagnostics Group Co has tested 154,000 COVID-19 nucleic acid specimens.

In addition, it has also launched other assistance projects to help with the diagnosis of COVID-19.